Adolescents with SCD admitted to US children’s hospitals, PHIS, 2010-2021
Characteristic | |
Unique patients | 7202 |
Unique admissions | 34 094 |
Age at first admission median (range) | 15.6 y (13.0-21.9) |
Male sex, n (%) | 3549 (49.3) |
Race, n (%) | |
Black | 6507 (90.3) |
White | 184 (2.6) |
Other/Unknown | 511 (7.1) |
Ethnicity, n (%) | |
Non-Hispanic/Latino | 6418 (89.1) |
Hispanic/Latino | 328 (4.6) |
Unknown | 456 (6.3) |
Insurance type, n (%) | |
Public | 4829 (67.1) |
Private | 2061 (28.6) |
Other (self-pay, charity) | 255 (3.5) |
Unknown | 56 (0.8) |
Region, n (%) | |
Midwest | 1604 (22.3) |
Northeast | 1138 (15.8) |
South | 3723 (51.7) |
West | 737 (10.2) |
Sickle Cell Genotype∗ , n (%) | |
SS | 4951 (68.7) |
SC | 1068 (14.8) |
Sβ thalassemia | 663 (9.2) |
Nonspecific/other† | 520 (7.2) |
Characteristic | |
Unique patients | 7202 |
Unique admissions | 34 094 |
Age at first admission median (range) | 15.6 y (13.0-21.9) |
Male sex, n (%) | 3549 (49.3) |
Race, n (%) | |
Black | 6507 (90.3) |
White | 184 (2.6) |
Other/Unknown | 511 (7.1) |
Ethnicity, n (%) | |
Non-Hispanic/Latino | 6418 (89.1) |
Hispanic/Latino | 328 (4.6) |
Unknown | 456 (6.3) |
Insurance type, n (%) | |
Public | 4829 (67.1) |
Private | 2061 (28.6) |
Other (self-pay, charity) | 255 (3.5) |
Unknown | 56 (0.8) |
Region, n (%) | |
Midwest | 1604 (22.3) |
Northeast | 1138 (15.8) |
South | 3723 (51.7) |
West | 737 (10.2) |
Sickle Cell Genotype∗ , n (%) | |
SS | 4951 (68.7) |
SC | 1068 (14.8) |
Sβ thalassemia | 663 (9.2) |
Nonspecific/other† | 520 (7.2) |
This table excludes 427 patients who were documented as having VTE.
Determined by ICD coding. For patients who had multiple genotypes coded throughout the study period, the genotype that was used most frequently was chosen.
Includes nonspecific and not elsewhere classifiable SCD diagnosis codes as well as instances of a tie for the most frequently used genotype and the method described in the previous footnote could not be applied.